3-nitropropionic acid as a tool to study the mechanisms involved in huntington's disease: Past, present and future

Molecules

Volumn 15, Issue 2, 2010, Pages 878-916

  Túnez, Isaac ^a   Tasset, Inmaculada ^a   La Cruz, Verónica Pérez De ^b   Santamaría, Abel ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

3 nitropropionic acid; Huntington's disease; Quinolinic acid; Succinate dehydrogenase; Transgenic mice models

Indexed keywords

3 NITROPROPIONIC ACID; 3-NITROPROPIONIC ACID; NITRO DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ANIMAL; ARTICLE; DISEASE MODEL; HUMAN; HUNTINGTON CHOREA; METABOLISM;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; NITRO COMPOUNDS; PROPIONIC ACIDS;

EID: 77649215222     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15020878     Document Type: Article

References (271)

1. Gonzalez-Alegre, P.; Afifi, A.K. Clinical characteristics of childhood-onset (juvenile) Huntington disease: Report of 12 patients and review of the literature. J. Child. Neurol. 2006, 21, 223-229.
2. Avila-Giron, R. Medical and social aspects of Huntington's chorea in the state of Zulia, Venezuela. Adv. Neurol. 1973, 1, 261-266.
3. González-Ferrer, S.; Pineda-Bernal, L.; Delgado-Luengo, W.; Villalobos-Cabrera, H. Medical genetics in Zulia, a State of Venezuela. Community Genet. 2004, 7, 153-156.
4. Okun, M.S.; Thommi, N. Americo Negrette (1924 to 2003): Diagnosing Huntington disease in Venezuela. Neurology 2004, 63, 340-343.
5. Paradisi, I.; Hernández, A.; Arias, S. Huntington disease mutation in Venezuela: Age of onset, haplotype analyses and geographic aggregation. J. Hum. Genet. 2008, 53, 127-135.
6. Pridmore, S.; Cook, A.; McCormick, G.; West, A.Trinucleotide expansion in Tasmanian HD families. Aust. N Z J. Psychiat. 1995, 29, 157.
7. Pridmore, S.A.The large Huntington's disease family of Tasmania. Med. J. Aust. 1990a, 153, 593-595.
8. Pridmore, S.A. The prevalence of Huntington's disease in Tasmania. Med. J. Aust. 1990b, 153, 133-134.
9. Wright, H.H.; Still, C.N.; Abramson, R.K. Huntington's disease in black kindreds in South Carolina. Arch. Neurol. 1981, 38, 412-414.
10. Young, A.B.; Shoulson, I.; Penney, J.B.; Starosta-Rubinstein, S.; Gomez, F.; Travers, H.; Ramos- Arroyo, M.A.; Snodgrass, S.R.; Bonilla, E.; Moreno, H.; Wexler, N.S. Huntington's disease in Venezuela: Neurologic features and functional decline. Neurology 1986, 36, 244-249.
11. Aubeeluck, A.; Brewer, H. Huntington's disease. Part 2: Treatment and management issues in juvenile HD. Br. J. Nurs. 2008, 17, 260-263.
12. Biglan, K.; Shoulson, I. Juvenile-onset Huntington disease: A matter of perspective. Arch. Neurol. 2007, 64, 783-784.
13. Foroud, T.; Gray, J.; Ivashina, J.; Conneally, P.M. Differences in duration of Huntington's disease based on age at onset. J. Neurol. Neurosurg. Psychiat. 1999, 66, 52-56.
14. Leegwater, J.; Jang-Ho, J. The paradigm of Huntington's disease: Therapeutic opportunities in neurodegeneration. Am. Soc. Exp. Neuro.Ther. 2004, 1, 128-138.
15. Nance, M.A.; Myers, R.H. Juvenile onset Huntington's disease-clinical and research perspectives. Ment. Retard Dev. Disabil. Res. Rev. 2001, 7, 153-157.
16. Ribaï, P.; Nguyen, K.; Hahn-Barma, V.; Gourfinkel-An, I.; Vidailhet, M.; Legout, A.; Dodé, C.; Brice, A.; Dürr, A. Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch. Neurol. 2007, 64, 813-819.
17. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72, 971-983.
18. Arnulf, I.; Nielsen, J.; Lohmann, E.; Schiefer, J.; Wild, E.; Jennum, P.; Konofal, E.; Walker, M.; Oudiette, D.; Tabrizi, S.; Durr, A. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65, 482-488.
19. Björkqvist, M.; Wild, E.J.; Thiele, J.; Silvestroni, A.; Andre, R.; Lahiri, N.; Raibon, E.; Lee, R.V.; Benn, C.L.; Soulet, D.; Magnusson, A.; Woodman, B.; Landles, C.; Pouladi, M.A; Hayden, M.R.; Khalili-Shirazi, A.; Lowdell, M.W.; Brundin, P.; Bate, G.P.; Leavitt, B.R.; Möller, T.; Tabrizi, S.J. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008, 205, 1869-1877.
20. Eskenazi, B.R.; Wilson-Rich, N.S.; Starks, P.T. A Darwinian approach to Huntington's disease: Subtle health benefits of a neurological disorder. Med. Hypoth.2007, 71, 151-152.
21. Gaba, A.M.; Zhang, K.; Marder, K.; Moskowitz, C.B.; Werner, P.; Boozer, C.N. Energy balance in early-stage Huntington disease. Am. J. Clin. Nutr. 2005, 81, 1335-1341.
22. Folstein, S.E.; Leigh, R.J.; Parhad, I.M.; Folstein, M.F. The diagnosis of Huntington's disease. Neurology 1986, 36, 1279-1283.
23. Johnson, S.A.; Stout, J.C.; Solomon, A.C.; Langbehn, D.R.; Aylward, E.H.; Cruce, C.B.; Ross, C.A.; Nance, M.; Kayson, E.; Julian-Baros, E.; Hayden, M.R.; Kieburtz, K.; Guttman, M.; Oakes, D.; Shoulson, I.; Beglinger, L.; Duff, K.; Penziner, E.; Paulsen, J.S. Predict-HD Investigators of the Huntington Study Group. Beyond disgust: Impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain 2007, 130, 1732-1744.
24. Martin, J.B.; Gusella, J.F. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 1986, 315, 1267-1276.
25. Morton, A.J.; Wood, N.I.; Hastings, M.H.; Hurelbrink, C.; Barker, R.A.; Maywood, E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005, 25, 3994.
26. Phillips, W.; Shannon, K.M.; Barker, R.A. The current clinical management of Huntington's disease. Mov. Disord. 2008, 23, 1491-1504.
27. Purdon, S.E.; Mohr, E.; Ilivitsky, V.; Jones, B.D. Huntington's disease: Pathogenesis, diagnosis and treatment. J. Psychiatry Neurosci. 1994, 19, 359-367.
28. Roze, E.; Saudou, F.; Caboche, J. Pathophysiology of Huntington's disease: From huntingtin functions to potential treatments. Curr. Opin. Neurol. 2008, 21, 497-503.
29. Sandyk, R. Pineal and habenula calcification in schizophrenia. Int. J. Neurosci. 1992, 67, 19-30.
30. Shiwach, R.S.; Norbury, C.G. A controlled psychiatric study of individuals at risk for Huntington's disease. Br. J. Psychiatry 1994, 165, 500-505.
31. Van Duijn, E.; Kingma, E.M.; van der Mast, R.C. Psychopathology in verified Huntington's disease gene carriers. J. Neuropsychiatry. Clin. Neurosci. 2007, 19, 441-448.
32. Walker, F. Huntington's disease. Lancet 2007, 369, 218-228.
33. Cha, J.H. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 2000, 23, 387-392.
34. La Spada, A.R.; Roling, D.B.; Harding, A.E.; Warner, C.L.; Spiegel, R.; Hausmanowa- Petrusewicz, I.; Yee, W.C.; Fischbeck. K.H. Meiotic stability and genotype-phenotype correlation of the trinucleotide repeat in X-linked spinal and bulbar muscular atrophy. Nat. Genet. 1992, 2, 301-304.
35. DiFiglia, M.; Sapp, E.; Chase, K.O.; Davies, S.W.; Bates, G.P.; Vonsattel, J.P.; Aronin, N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277, 1990-1993.
36. Rangone, H.; Humbert, S.; Saudou, F. Huntington's disease: How does huntingtin, an antiapoptotic protein, become toxic? Pathol. Biol. (Paris) 2004, 52, 338-342.
37. Brouillet, E.; Condé, F.; Beal, M.F.; Hantraye, P. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 1999, 59, 427-468.
38. Chiarugi, A.; Calvani, M.; Meli, E.; Traggiai, E.; Moroni, F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 2001a, 120, 190-198.
39. Chiarugi, A.; Meli, E.; Moroni,; F. Similarities and differences in the neural death processes activated by 3OH-Kynurenine and quinolinic acid. J. Neurochem. 2001b, 77, 1310-1318.
40. Estrada-Sánchez, A.M.; Mejía-Toiber, J.; Massieu, L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch. Med. Res. 2008, 39, 265-276.
41. Dawson, R.; Beal, M.F.; Bondy, S.C.; Di Monte, D.A.; Isom, G.E. Excitotoxins, aging, and environmental neurotoxins: Implications for understanding human neurodegenerative diseases. Toxicol. Appl. Pharmacol. 1995, 134, 1-17.
42. Guidetti, P.; Bates, G.P.; Graham, R.K.; Hayden, M.R.; Leavitt, B.R.; MacDonald, M.E.; Slow, E.J.; Wheeler, V.C.; Woodman, B.; Schwarcz, R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol. Dis. 2006, 23, 190-197.
43. Pérez-de la Cruz, V.; Santamaría, A. Integrative hypothesis for Huntington's disease: A brief review of experimental evidence. Physiol. Res. 2007b, 56, 513-526.
44. Brouillet, E.; Jacquard, C.; Bizat, N.; Blum, D. 3-Nitropropionic acid: A mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 2005, 95, 1521-1540.
45. Brennan, W.A.Jr.; Bird, E.D.; Aprille, J.R. Regional mitochondiral respieratoy activity in Huntington's disease brain. J. Neurochem. 1985, 44, 1948-1950.
46. Parker, W.D.Jr.; Baoyson, S.J.; Luder, A.S.; Parks, J.K. Evidence for a defect in NADH: Ubiquinone oxidoreductase (complex I) in Huntington's disease. Neurology 1990, 40, 1231-1234.
47. Arenas, J.; Campos, Y.; Ribacoba, R.; Martín, M.A.; Rubio, J.C.; Ablanedo, P.; Cabello, A. Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol. 1998, 43, 397-400.
48. Kumar, P.; Kumar A. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: Possible behavioural, biochemical and cellular alterations. Eur. J. Pharmacol. 2009, 615, 91-101.
49. Túnez, I.; Santamaría, A. Model of Huntington's disease induced with 3-nitropropionic acid. Rev. Neurol. 2009, 48, 430-434.
50. Tasset, I.; Sánchez, F.; Túnez, I. The molecular bases of Huntington's disease: The role played by oxidative stress. Rev. Neurol. 2009, 49, 424-429.
51. Gil, J.M.; Rego, A.C. Mechanisms of neurodegeneration in Huntington's disease. Eur. J. Neurosci. 2008, 27, 2803-2820.
52. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38, 357-366.
53. Banoei, M.M.; Houshmand, M.; Panahi, M.S., Shariati, P.; Rostami, M.; Manshadi, M.D.;Majidizadeh, T. Huntington's disease and mitochondrial DNA deletions: Event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?! Cell. Mol. Neurobiol. 2007, 27, 867-875.
54. Lim, D.; Fedrizzi, L.; Tartari, M.; Zuccato, C.; Cattaneo, E.; Brini, M.; Carafoli, E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J. Biol. Chem. 2008, 283, 5780-5789.
55. Kalonia, H.; Kumar, P.; Kumar, A.; Nehru, B. Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. Neurosci. Bull. 2009, 25, 343-352.
56. Kumar, P.; Kalonia, H.; Kumar, A. Lycopene modulates nitric oxide pathways against 3-nitropropioni acid-induced neurotoxicity. Life Sci. 2009, 85, 711-718.
57. Kumar, P.; Kumar, A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: Possible role of nitric oxide. Behav. Brain Res. 2010, 38-46.
58. Browne, S.E. Mitochondrial and Huntingon's disease pathogenesis: Insight from genetic and chemical models. Ann. N.Y. Acad. 2008, 1147, 358-382.
59. Vonsattel, J.P.; Myers, R.H.; Stevens, T.J.; Ferrante, R.J.; Bird, E.D.; Richardson, E.P., Jr. Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 1985, 44, 559-577.
60. Bence, N.F.; Sampat, R.M.; Kopito, R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2001, 292, 1552-1555.
61. Finkbeiner, S.; Mitra, S. The ubiquitin-proteasome pathway in Huntington's disease. Sci.Word J. 2008, 8, 421-433.
62. Gafni, J.; Hermel, E.; Young, J.E.; Wellington, C.L.; Hayden, M.R.; Ellerby, L.M. Inhibition of calpain cleavage of huntingtin reduces toxicity: Accumulation of calpain/caspase fragments in the nucleus J. Biol. Chem. 2004, 279, 20211-20220.
63. Lunkes, A.; Lindenberg, K.S.; Ben-Haïem, L.; Weber, C.; Devys, D.; Landwehrmeyer, G.B.; Mandel, J.L.; Trottier, Y. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell. 2002, 10, 259-269.
64. Sánchez, I.; Mahlke, C.; Yuan, J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003, 421, 373-379.
65. Poirier, M.A.; Li, H.; Macosko, J.; Cai, S.; Amzel, M.; Ross, C.A. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 2002, 277, 41032-41037.
66. Poirier, M.A.; Jiang, H.; Ross, C.A. A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: Evidence for a compact beta-sheet structure. Hum. Mol. Genet. 2005, 14, 765-774.
67. Ross, C.A.; Pickart, C.M. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004, 14, 703-711.
68. Venkatraman, P.; Wetzel, R.; Tanaka, M.; Nukina, N.; Goldberg, A.L Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutaminecontaining proteins. Mol. Cell. 2004, 14, 95-104.
69. Canals, J.M.; Pineda, J.R.; Torres-Peraza, J.F.; Bosch, M.; Martín-Ibáñez, R.; Muñoz, M.T.; Mengod, G.; Ernfors, P.; Alberch, J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 2004, 24, 7727-7739.
70. Cattaneo, E. Dysfunction of wild-type huntingtin in Huntington disease. News Physiol. Sci. 2003, 18, 34-37.
71. Jiang, H.; Poirier, M.A.; Liang, Y.; Pei, Z.; Weiskittel, C.E.; Smith, W.W.; DeFranco, D.B.; Ross, C.A. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol. Dis. 2006, 23, 543-551.
72. Kegel, K.B.; Meloni, A.R; Yi, Y.; Kim, Y.J., Doyle, E.; Cuiffo, B.G.; Sapp, E.; Wang, Y., Qin, Z.H.; Chen, J.D.; Nevins, J.R.; Aronin, N.; DiFiglia, M. Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 2002, 277, 7466-7476.
73. Lee, S.T.; Kim, M. Aging and neurodegeneration. Molecular mechanisms of neuronal loss in Huntington's disease. Mech Ageing Dev. 2006, 127, 432-435.
74. Liu, Y.F.; Deth, R.C.; Devys, D. SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signalling complexes. J. Biol. Chem. 1997, 272, 8121-8124.
75. Martindale, D.; Hackam, A.; Wieczorek, A.; Ellerby, L., Wellington, C.; McCutcheon, K., Singaraja, R.; Kazemi-Esfarjani, P.; Devon, R.; Kim, S.U.; Bredesen, D.E.; Tufaro, F.M ; Hayden, M.R. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 1998, 18, 150-154.
76. Ross, C.A.; Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10, S10-S17.
77. Scappini, E.; Koh, T.W.; Martin, N.P.; O'Bryan, J.P. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum. Mol. Genet. 2007, 16, 1862-1871.
78. Steffan, J.S.; Agrawal, N.; Pallos, J.; Rockabrand, E.; Trotman, L.C.; Slepko, N.; Illes K, Lukacsovich, T.; Zhu, Y.Z.; Cattaneo, E.; Pandolfi, P.P.; Thompson, L.M.; Marsh, J.L. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304, 100-104.
79. Sugars, K.L.; Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003, 19, 233-238.
80. Zuccato, C.; Liber, D.; Ramos, C.; Tarditi, A.; Rigamonti, D.; Tartari, M.; Valenza, M.; Cattaneo, E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 2003, 52, 133-139.
81. Coyle, J.T.; Schwarcz, R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 1976, 263, 244-246.
82. Rothman, S.M.; Olney, J.W. Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 1995, 18, 57-58.
83. Mangiarini, L.; Sathasivam, K.; Seller, M., Cozens, B.; Harper, A.; Hetherington, C., Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S.W.; Bates, G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87, 493-506.
84. Parker, J.A.; Connolly, J.B.;Wellington, C.; Hayden, M.; Dausset, J.; Neri, C. Expanded poluglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. USA 2001, 98, 13318-13323.
85. Marsh, J.L.; Pallos, J.; Thompson, L.M. Fly models of Huntington's disease. Hum. Mol. Genet. 2003, 2, R187-R193.
86. Powers, W.J.; Videen, T.O.; Markham, J.; McGee-Minnich, L.; Antenor-Dorsey, J.V.; Hershey, T.; Perlmutter, J.S. Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. USA 2007, 104, 2945-2949.
87. Beal, M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 2007, 31, 119-130.
88. Hamilton, B.F.; Gould, D.H. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage. Acta Neuropathol. 1987, 72, 286-297.
89. Liu, X.; Luo, X.; Hu, W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed. Environ. Sci. 1992, 5, 161-177.
90. Ramaswamy, S.; McBrid, J.L.; Kordower, J.H. Animal models of Huntington's disease. ILAR. J. 2007, 48, 356-373.
91. Borlongan, C.V.; Koutouzis, T.K.; Freeman, T.B.; Hauser, R.A.; Cahill, D.W.; Sanberg, R. Hyperactivity and hypoactivity in a rat model of Huntington's disease: The systemic 3-nitropropionic acid model. Brain Res. Brain Res. Protoc. 1997a, 1, 253-257.
92. Ouary, S.; Bizat, N.; Altairac, S.; Ménétrat, H.; Mittoux,V.; Condé, F.; Hantraye, P.; Brouillet, E. Major strain differences in response to chronic systemic administration of the mitochondrialtoxin 3-nitropropionic acid in rats: Implications for neuroprotection studies. Neuroscience 2000, 97, 521-530.
93. Ahuja, M.; Bishnoi, M.; Chopra, K. Protective effect of minocycline, a semi-synthetic secondgeneration tetracycline against 3-nitropropionic acid (3-NP)-induced neurotoxicity. Toxicology 2008, 244, 111-122.
94. Deshpande, S.B.; Hida, H.; Takei-Io, N.; Masuda ,T.; Baba, H.; Nishino, H. Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res. 2006, 1108, 205-215.
95. Dhir, A.; Akula, KK.; Kulkarni, S.K.; Tiagabine, A. GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 835-843.
96. Lukács, A.; Szabó, A.; Vezér, T.; Papp, A. The acute effects of 3-nitropropionic acid on the behavior and spontaneous cortical electrical activity of rats. Acta Neurobiol. Exp. (Wars). 2006, 66, 227-233.
97. McBride, J.L.; During, M.J.; Wuu .J.; Chen, E.Y.; Leurgans, S.E.; Kordower, J.H. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp. Neurol. 2003, 181, 213-223.
98. Mogami, M.; Hayashi, Y.; Masuda, T.; Kohri, K.; Nishino, H.; Hida, H. Altered striatal vulnerability to 3-nitropropionic acid in rats due to sex hormone levels during late phase of brain development. Neurosci. Lett. 2008, 436, 321-325.
99. Przybyla-Zawislak, B.D.; Thorn, B.T.; Ali, S.F.; Dennis, R.A.; Amato, A.; Virmani A.; Binienda, Z.K. Identification of rat hippocampal mRNAs altered by the mitochondrial toxicant, 3-NPA. Ann. N. Y. Acad. Sci. 2006, 1053, 162-173.
100. Túnez, I.; Collado, J.A.; Medina, F.J.; Peña, J.; Muñoz, M.C.; Jimena, I.; Franco, F.; Rueda, I.; Feijóo, M.; Muntané, J.; Montilla, P. 17 Beta-estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats. Neurochem. Int. 2006a, 48, 367-373.
101. Túnez, I.; Drucker-Colín, R.; Jimena, I.; Medina, F.J.; Muñoz, M.C.; Peña, J.; Montilla, P. Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease. J. Neurochem. 2006b, 97, 619-630.
102. Túnez, I.; Feijóo, M.; Collado, J.A.; Medina, F.J.; Peña, J.; Muñoz, M.C.; Jimena, I.; Franco, F.; Rueda, I.; Muntané, J.; Montilla, P. Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats. Life Sci. 2007, 80, 1221-1227.
103. Túnez, I.; Montilla, P.; Muñoz, M.C.; Feijóo, M.; Salcedo, M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J. Pineal Res. 2004b, 37, 252-256.
104. Túnez, I.; Montilla, P.; Muñoz, M.C.; Drucker-Colín, R. Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur. J. Pharmacol. 2004a, 504, 169-175.
105. Túnez, I.; Muñoz, M.C.; Montilla, P. Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 2005, 74, 113-118.
106. Shih, A.Y.; Imbeault, S.; Barakauskas, V.; Erb, H.; Jiang, L.; Li, P.; Murphy, T.H. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J. Biol. Chem. 2005, 280, 22925-22936.
107. Borlongan, C.V.; Koutouzis T.K.; Sanberg P.R. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci. Biobehav. Rev. 1997b, 21, 289-293.
108. Beal, M.F.; Brouillet, E,; Jenkins, B.G.; Ferrante, R.J.; Kowall, N.W.; Miller, J.M.; Storey, E.; Srivasta, R.; Rosen, B.R; Hyman, B.T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-ntropropionic acid. J. Neurosci. 1993, 13, 4181-4192
109. Guyot, M.C.; Hantraye, P., Dolan, R.; Palfi S., Maziére, M.; Brouillet, E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience 1997, 79, 45-56.
110. Hamilton, B.F.; Gould, D.H. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: A type of hypoxic (energy deficient) brain damage. Acta Neuropathol. 1987, 72, 286-297.
111. Beal, M.F. Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 1994, 7, 542-547.
112. Brouillet, E.; Guyot, M.C.; Mittoux, V.; Altairac, S.; Conde, F.; Palfi, S.; Hantraye, P. Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 1998, 70, 794-805.
113. Borlongan, C.V.; Koutouzis, T.K.; Freeman, T.B.; Cahill, D.W.; Sanberg, P.R. Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. Brain Res. 1995a, 697, 254-257.
114. Borlongan, C.V.; Koutouzis, T.K., Randall, T.S; Freeman, T.B., Cahill, D.W.; Sanberg, P.R. Systemic 3-nitropropionic acid: Behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 1995b, 6, 549-556.
115. Brouillet, E.; Hantraye, P.; Ferrante, R.J.; Dolan R.; Leroy-Willig, A.; Kowall, N.W.; Beal, M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. USA 1995, 92, 7105-7109.
116. Mettler, F.A. Choreoathetosis and striopallidonigral necrosis due to sodium azide. Exp. Neurol. 1972, 34, 291-308.
117. Palfi, S.; Ferrante, R.J.; Brouillet, E.; Beal M.F.; Dolan, R.; Guyot, M.C.; Peschanski, M.; Hantraye, P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci. 1996, 16, 3019-3025.
118. Stober, T., Wussow, W.; Schimrigk, K. Bicaudate diameter the most specific and simple CT parameter in the diagnosis of Huntington's disease. Neuroradiology 1984, 26, 25-28.
119. Ming, L. Moldy sugarcane poisoning-a case report with a brief review. J. Toxicol. Clin. Toxicol. 1995, 33, 363-367.
120. Ludolph, A.C.; He, F.; Spencer, P.S.; Hammerstad, J.; Sabri, M. 3-Nitropropinic acid-exogenous animal neurotoxin and possible human striatal toxin. Can. J. Neurol. Sci. 1991, 18, 492-498.
121. Alston, T.A.; Mela, L.; Bright, H.J. Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc. Natl. Acad. Sci. USA 1977, 74, 3767-3771.
122. Browne, S.E.; Bowling, A.C.; MacGarvey, U.; Baik, M.J.; Berger, S.C.; Muqit, M.M.; Bird, E.D.; Beal. M. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41, 646-653.
123. Gu, M.; Gash, M.T.; Mann, V.M; Javoy-Agid F.; Cooper, J.M.; Schapira, A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 1996, 39, 385-389.
124. Tabrizi, S.J.; Cleeter, M.W., Xuereb, J.; Taanman, J.W.; Cooper, J.M.; Schapira, A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45, 25-32.
125. Lee, J.M.; Shih, A.Y.; Murphy, T.H.; Johnson, J.A. NF-E2-related factor-2 mediates neuroprotection against mitochondrial complex I inhibitors and increased concentrations of intracellular calcium in primary cortical neurons. J. Biol. Chem. 2003, 278, 37948-37956.
126. 2+, ATP, mitochondrial membrane potential, and calpain activity on the mechanism on neuron death induced by 3-nitropropionic acid. Neurochem. Int. 2003, 43, 89-99.
127. 2+ and respiratory chain complex II inhibition. J. Neurochem. 2004, 90, 1025-1035.
128. Galas, M.C.; Bizat, N.; Cuvelier, L.; Bantubungi, K.; Brouillet E.; Schiffmann, S.N.; Blum, D. Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurol. Dis. 2004, 15, 152-159.
129. Alexi, T.; Hughes, P.E.; Faull, R.L.; Williams, C.E. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeneration. NeuroReport 1998, 9, R57-R64.
130. 2+ exchanger. Exp. Neurol. 1997, 145, 38-45.
131. 2+ overload induced by a mitochondrial toxin, 3-nitropropionic acid. Neuroscience 1998, 87, 497-507.
132. Montilla, P.; Túnez, I.; Muñoz, M.C.; Salcedo. M.; Feijóo, M.; Muñoz-Castañeda, J.R.; Bujalance, I. Effect of glucocorticoids on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur. J. Pharmacol. 2004, 488, 19-25.
133. Lafon-Cazal, M.; Pietri, S.; Culcasi, M.; Bockaert, J. NMDA-dependent superoxide production and neurotoxicity. Nature 1993, 364, 535-537.
134. La Fontaine, M.A.; Geddes, J.W.; Banks, A.; Butterfield D.A. 3-Nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: Insights into Huntington's disease. Brain Res. 2000, 858, 356-362.
135. Marti, M.; Mela, F.; Ulazzi, L.; Hanau, S.; Stocchi, S.; Paganini, F.; Beani, L.; Bianchi, C.; Morari, M. Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: Implications for Huntington's disease. Eur. J. Neurosci. 2003, 18, 759-767.
136. Storgaard, J.; Kornblit, BT.; Zimmer, J; Gramsbergen, J.B. 3-Nitropropionic acid neurotoxicity in organotypic striatal and corticostriatal slice cultures is dependent on glucose and glutamate. Exp. Neurol. 2000, 164, 227-235.
137. Novelli, A.; Reilly, A.; Lysk, P.G.; Henneberry, R.C. Glutamate becomes neurotoxic via the Nmethyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451, 205-212.
138. Beal, M.F.; Kowall, N.W.; Ellison, D.W.; Mazurek, M.F.; Swartz, K.J.; Martin, J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 1986, 321, 168-171.
139. Nasr, P.; Carbery, T.; Geddes, J.W. N-methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem. Res. 2009, 34, 490-498.
140. Moro, M.A.; De Alba, J.; Cárdenas, A.; De Cristóbal, J.; Leza, J.C.; Lizasoain, I.M.; Díaz-Guerra, M.J.; Boscá, L.; Lorenzo, P. Mechanisms of the neuroprotective effect of aspirin after oxygen and glucose deprivation in rat forebrain slices. Neuropharmacology 2000, 39, 1309-1318.
141. Ryu, J.K.; Nagai, A.; Kim, J.; Lee, M.C.; McLarnon, J.G.; Kim, S.U. Microglial activation and cell death induced by the mitochondial toxin 3-nitropropionic acid: In vitro and in vivo studies. Neurobiol. Dis. 2003, 12, 121-132.
142. Ohgoh, M.; Shimizu, H.; Ogura, H.; Nishizawa, Y. Astroglial trophic support and neuronal cell death: influence of cellular energy level on type of cell death induced by mitochondrial toxin in cultured rat cortical neurons. J. Neurochem. 2000, 75, 925-933.
143. Mittoux, V.; Ouary, S.; Monville, C.; Lisovoski, F.; Poyot, T.; Conde, F.; Escartin, C.; Robichon, R.; Brouillet, E.; Peschanski, M.; Hantraye, P. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration. J. Neurosci. 2002, 22, 4478-4486.
144. Villarán, R.F.; Tomás-Camardiel, M.; de Pablos, R.M.; Santiago, M.; Herrera, A.J.; Navarro, A.; Machado, A.; Cano, J. Endogenous dopamine enhances the neurotoxicity of 3-nitropropionic acid in the striatum through the increase of mitochondrial respiratory inhibition and free radicals production. Neurotoxicology 2008, 29, 244-258.
145. Nishino, H.; Kumazaki, M.; Fukuda, A.; Fujimoto, I.; Shimano,Y.; Hida, H.; Sakurai, T.; Deshpande, S.B.; Shimizu, H.; Morikawa, S.; Inubushi, T. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: Involvement of dopamine toxicity. Neurosci. Res. 1997, 27, 343-355.
146. McCracken, E.; Dewar, D.; Hunter, A.J. White matter damage following systemic injection of the mitochondrial inhibitor 3-nitropropionic acid in rat. Brain Res. 2001, 892, 329-335.
147. Sato, S.; Gobbel, G.T.; Honkaniemi, J.; Li, Y.; Kondo, T.;Murakami ,K.; Sato, M.; Copin, J.C.; Chan, P.H. Apoptosis in the striatum of rats following intraperitoneal injection of 3-nitropropionic acid. Brain Res. 1997, 745, 343-347.
148. Sato, S.; Gobbel, G.T.; Li ,Y.; Kondo, T.; Murakami, K.; Sato, M.; Hasegawa, K.; Copin, J.C.; Honkaniemi, J.; Sharp, F.R.; Chan, P.H. Blood-brain barrier disruption, HSP70 expression and apoptosis due to 3-nitropropionic acid, a mitochondrial toxin. Acta Neurochir. Suppl. 1997, 70, 237-239.
149. Bantubungi, K.; Jacquard, C.; Greco, A.; Pintor, A.; Chtarto, A.; Tai ,K.; Galas, M.C.; Tenenbaum, L.; Déglon, N.; Popoli, P.; Minghetti, L.; Brouillet, E.; Brtchi, J.; Levivier, M.; Schiffmann, S.N.; Blum, D. Minocycline in phenotypic models of Huntington's disease. Neurobiol. Dis. 2005, 18, 206-217.
150. Nishino, H.; Hida, H.; Kumazaki, M.; Shimano, Y.; Nakajima, K.; Shimizu, H.; Ooiwa, T.; Baba, H. The striatum is the most vulnerable region in the brain to mitochondrial energy compromise: A hypothesis to explain its specific vulnerability. J. Neurotrauma 2000, 17, 251-260.
151. Halliwell, B. Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006, 97, 1634-1658.
152. Moncada, S.; Bolaños, J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 97, 1676-1689.
153. Coles, C.J.; Edmondson, D.E.; Singer, T.P. Inactivation of succinate dehydrogenase by 3-nitropropionate. J. Biol. Chem. 1979, 254, 5161-5167.
154. Beal, M.F.; Hyman, B.T.; Koroshetz, W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993, 16, 125-131.
155. Palfi, S.; Leventhal, L.; Goetz, C.G.; Hantraye, T.; Roitberg, B.Z.; Sramek, J.; Emborg, M.; Kordower, J.H. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov. Disord. 2000, 15, 524-530.
156. Yang, L.; Calingasan, N.Y.; Chen, J.; Ley, J.J.; Becker, D.A.; Beal, M.F. A novel azulenyl nitrone antioxidant protects against MPTP and 3-nitropropionic acid neurotoxicities. Exp. Neurol. 2005, 191, 86-93.
157. Binienda, Z.; Simmons, C.; Hussain, S.; Slikker, W. Jr.; Ali, S.F. Effect of acute exposure to 3-nitropropionic acid on activities of endogenous antioxidants in the rat brain. Neurosci. Lett. 1998, 251, 173-176.
158. Herrera-Mundo, M.N.; Silva-Adaya, D.; Maldonado, P.D.; Galván-Arzate, S.; Andrés-Martínez, L.; Pérez-de la
159. Nam, E.; Lee, S.M.; Koh, S.E.; Joo, W.S.; Maeng, S.; Im, H.I.; Kim, Y.S. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res. 2005, 1046, 90-96.
160. Pérez-de la Cruz, V.; González-Cortés, C.; Pedraza-Chaverrí, J.; Maldonado, P.D.; Andrés- Martínez, L.; Santamaría, A. Protective effect of S-allylcysteine on 3-nitropropionic acid-induced lipid peroxidation and mitochondrial dysfunction in rat brain synaptosomes. Brain Res. Bull. 2006, 68, 379-383.
161. Schulz, J.B.; Henshaw, D.R.; MacGarvey, U.; Beal, M.F. Involvement of oxidative stress in 3- nitropropionic acid neurotoxicity. Neurochem. Int. 1996, 29, 167-171.
162. Pérez-De La Cruz, V.; Konigsberg, M.; Pedraza-Chaverri, J.; Herrera-Mundo, N.; Díaz-Muñoz, M.; Morán, J.; Fortoul-van der Goes, T.; Rondán-Zárate, A.; Maldonado, P.D.; Ali, S.F.; Santamaría, A. Cytoplasmic calcium mediates oxidative damage in an excitotoxic/energetic deficit synergic model in rats. Eur. J. Neurosci. 2008, 27, 1075-1085.
163. Ferdinandy, P.; Schulz, R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemiareperfusion injury and preconditioning. Br. J. Pharmacol. 2003, 138, 532-543.
164. Blum, D.; Gall, D.; Cuvelier, L.; Schiffmann, S.N. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Neuroreport 2001, 12, 1769-1772.
165. Pang, Z.; Geddes, J.W. Mechanisms of cell death induced by the mitochondrial toxin 3- nitropropionic acid: Acute excitotoxic necrosis and delayed apoptosis. J. Neurosci. 1997, 17, 3064-3073.
166. Bossi, S.R.; Simpson, J.R.; Isacson, O. Age dependence of striatal neuronal death caused by mitochondrial dysfunction. Neuroreport 1993, 4, 73-76.
167. Koutouzis, T.K.; Borlongan, C.V.; Scorcia, T.; Creese, I.; Cahill, D.W.; Freeman, T.B.; Sanberg, P.R. Systemic 3-nitropropionic acid: Long-term effects on locomotor behavior. Brain Res. 1994, 646, 242-246.
168. Filloux, F.; Townsend, J.J. Pre- and postsynaptic neurotoxic effects of dopamine demostrated by intrastriatal injection. Exp. Neuro. 1993, 119, 79-88.
169. Reynolds, D.S.; Carter, R.J.; Morton, A.J. Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease. J. Neurosci. 1998, 18, 10116-10127.
170. Maragos, W.F.; Young, K.L.; Altman, C.S.; Pocernich, C.B.; Drake, J.; Butterfield, D.A.; Seif, I.; Holschneider, D.P.; Chen, K.; Shih, J.C. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem. Res. 2004, 29, 741-746.
171. Blum, D.; Hourez, R.; Galas, M.C.; Popoli, P.; Schiffmann, S.N. Adenosine receptors and Huntington's disease: Implications for pathogenesis and therapeutics. Lancet Neurol. 2003, 2, 366-374.
172. Lastres-Becker, I.; Fezza, F.; Cebeira, M.; Bisogno, T.; Ramos, J.A.; Milone, A.; Fernández-Ruiz, J.; Di Marzo, V. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport 2001, 12, 2125-2129
173. Lastres-Becker, I.; Gómez, M.; De Miguel, R.; Ramos, J.A.; Fernández-Ruiz, J. Loss of Cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease. Neurotox Res. 2002, 4, 601-608.
174. Canals, J.M.; Checa, N.; Marco, S.; Akerud, P.; Michels, A.; Pérez-Navarro, E.; Tolosa, E.; Arenas, E.; Alberch, J. Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. J. Neurosci. 2001, 21, 117-124.
175. Gauthier, L.R.; Charrin, B.C.; Borrell-Pagès, M.; Dompierre, J.P.; Rangone, H.; Cordelières, F.P.; De Mey, J.; MacDonald, M.E.; Lessmann, V.; Humbertm, S.; Saudou, F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118, 127-138.
176. Zuccato, C.; Ciammola, A.; Rigamonti, D.; Leavitt, B.R.; Goffredo, D.; Conti, L.; MacDonald, M.E; Friedlander ,RM.; Silani, V.; Hayden ,MR.; Timmusk, TÇ.; Sipione, S.; Cattaneo, E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293, 493-498.
177. Zuccato, C.; Tartari, M.; Crotti, A.; Goffredo, D.; Valenza, M.; Conti, L.; Cataudella, T.; Leavitt, B.R.; Hayden, M.R.; Timmusk, T.; Rigamonti, D.; Cattaneo, E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35, 76-83.
178. Zuccato, C.; Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol. 2007, 81, 294-330.
179. Altar, C.A.; Cai, N.; Bliven, T.; Juhasz, M.; Conner, J.M.; Acheson, A.L.; Lindsay, R.M.; Wiegand, S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 1997, 389, 856-860.
180. Kovalchuk, Y.; Hanse, E.; Kafitz , KW.; Konnerth, A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science 2002, 295, 1729-1734.
181. Ferrer, I.; Goutan, E.; Marín, C.; Rey, M.J.; Ribalta, T. Brain-derived neurotrophic factor in Huntington disease. Brain Res. 2000, 866, 257-261.
182. Ernfors, P.; Bramham, C.R. The coupling of a trkB tyrosine residue to LTP. Trends Neurosci. 2003, 26, 171-173.
183. Almli, C.R.; Levy, T.J.; Han, B.H.; Shah, A.R.; Gidday, J.M.; Holtzman, D.M. BDNF protects against spatial memory deficits following neonatal hypoxia-ischemia. Exp. Neurol. 2000, 166, 99-114.
184. Hock, C.; Heese, K.; Hulette, C.; Rosenberg, C.; Otten, U. Region-specific neurotrophin imbalances in Alzheimer disease: Decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 2000, 57, 846-851.
185. Hellweg, R.; von Arnim, C.A.; Büchner, M.; Huber, R.; Riepe, M.W. Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation. Exp. Neurol. 2003, 183, 346-354.
186. Cho, H.Y.; Jedlicka, A.E.; Reddy, S.P.; Kensler, T.W.; Yamamoto, M.; Zhang, L.Y.; Kleeberger, S.R. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 2002, 26, 175-182.
187. Gao, X.; Talalay, P. Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage. Proc. Natl. Acad. Sci. USA 2004, 101, 10446-10451.
188. Calkins, M.J.; Jakel, R.J.; Johnson, D.A.; Chan, K.; Kan, Y.W.; Johnson, J.A. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc. Natl. Acad. Sci. USA 2005, 102, 244-249.
189. Cullinan, S.B.; Diehl, J.A. PERK-dependent activation of Nrf2 contributes to redox homeostasisnd cell survival following endoplasmic reticulum stress. J. Biol. Chem. 2004, 279, 20108-20117.
190. Cullinan, S.B.; Zhang, D.; Hannink, M.; Arvisais, E.; Kaufman, R.J.; Diehl, J.A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol. 2003, 23, 7198-7209.
191. Kotlo, K.U.; Yehiely, F.; Harasty, H.; Hesabi, B.; Shchors, K.; Einat, P.; Rozen, A.; Berent, E.; Deiss, L.P. Nrf2 is an inhibitor of the Fas pathway as identified by Achilles'Hell Method, a new function-based approach to gene identification in human cells. Oncogene 2003, 22, 797-806.
192. Almeida, S.; Brett, A.C., Góis, I.N.; Oliveira, C.R.; Rego, A.C. Caspase-dependent and - independent cell death induced by 3-nitropropionic acid in rat cortical neurons. J. Cell Biochem. 2006, 98, 93-101.
193. Almeida, S.; Domingues, A.; Rodrigues, L.; Oliveira, C.R.; Rego, A.C. FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures. Neurobiol. Dis. 2004, 17, 435-444.
194. Enoksson, M.; Robertson, J.D.; Gogvadze, V.; Bu, P.; Kropotov, A.; Zhivotovsky, B.; Orrenius, S. Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J. Biol. Chem. 2004, 279, 49575-49578.
195. Garcia, M.; Vanhoutte, P.; Pages, C.; Besson, M.J.; Brouillet. E.; Caboche, J. The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-jun N-terminal kinase/c- Jun module. J. Neurosci. 2002, 22, 2174-2184.
196. Ichijo, H.; Nishida ,E.; Irie, K.; ten Dijke, P.; Saitoh, M.; Moriguchi, T.; Takagi, M.; Matsumoto, K.; Miyazono, K.; Gotoh, Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275, 90-94.
197. Minn, Y.; Cho, K.J.; Kim, H.W.; Kim, H.J.; Suk, S.H., Lee, B.I.; Kim, G.W. Induction of apoptosis signal-regulating kinase 1 and oxidative stress mediate age dependent vulnerability to 3-nitropropionic acid in the mouse striatum. Neurosci. Lett. 2008, 430, 142-146.
198. Pelegrí, C.; Duran-Vilaregut, J.; del Valle, J.; Crespo-Biel, N.; Ferrer, I.; Pallàs, M.; Camins, A.; Vilaplana, J. Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int. J. Dev. Neurosci. 2008, 26, 665-671.
199. Höglinger, G.U.; Breunig, J.J.; Depboylu ,C.; Rouaux, C.; Michel, P.P.; Alvarez-Fischer, D.; Boutillier, A.L.; Degregori, J.; Oertel, W.H.; Rakic, P.; Hirsch, E.C.; Hunot, S. The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc. Natl. Acad. Sci. USA. 2007, 104, 3585-3590.
200. Crespo-Biel, N.; Camins, A.; Pelegrí, C.; Vilaplana, J.; Pallàs, M.; Canudas, A.M. 3-Nitropropionic acid activates calpain/cdk5 pathway in rat striatum. Neurosci. Lett. 2007, 421, 77-81.
201. Park, D.S.; Obeidat, A.; Giovanni, A.; Greene, L.A. Cell cycle regulators in neuronal death evoked by excitotoxic stress: Implications for neurodegeneration and its treatment. Neurobiol. Aging 2000, 21, 771-781.
202. Seidel, B.; Jiang, L.; Wolf, G. Differentially displayed genes in neuroblastoma cells treated with a mitochondrial toxin: Evidence for possible involvement of ICAM-1 in 3-nitropropionic acidmediated neurodegeneration. Toxicol. Lett. 2000, 115, 213-222.
203. Napolitano, M.; Zei, D.; Centonze, D.; Palermo, R.; Bernardi, G.; Vacca, A.; Calabresi, P.; Gulino, A. NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: Implications for Huntington's disease. Neurosci. Lett. 2008, 434, 241-246.
204. García-Ramos, R.; del Val-Fernández, J.; Catalán-Alonso, M.J.; Barcia-Albacar, J.A., Matías- Guiu, J. Experimental models of Huntington's disease. Rev. Neurol. 2007, 45, 437-441.
205. Qin, Z.H.; Wang, J.; Gu, Z.L. Development of novel therapies for Huntington's disease: Hope and challenge. Acta Pharmacol. Sin. 2005, 26, 129-142.
206. Wang, L.H.; Qin, Z.H. Animal models of Huntington's disease: Implications in uncovering pathogenic mechanisms and developing therapies. Acta Pharmacol. Sin. 2006, 27, 1287-1302.
207. Leavitt, B.R.; van Raamsdonk, J.M.; Shehadeh, J.; Fernandes, H.; Murphy, Z.; Graham, R.K.; Wellington, C.L.; Raymond, L.A.; Hayden, M.R. Wild-type huntingtin protects neurons from excitotoxicity. J. Neurochem. 2006, 96, 1121-1129.
208. Sanberg, P.R.; Coyle, J.T. Scientific approaches to Huntington's disease. CRC Crit. Rev. Clin. Neurobiol. 1984, 1, 1-44.
209. Santamaría, A.; Jiménez, M.E. Oxidative/nitrative stress, a common factor in different neurotoxic paradigms: An overview. Curr. Topics Neurochem. 2006, 1-20.
210. Schwarcz, R.; Foster, A.C.; French, E.D.; Whetsell, W.O. Jr, Köhler, C. Excitotoxic models for neurodegenerative disorders. Life Sci. 1984, 35, 19-32.
211. Isacson, O.; Brundin, P.; Gage, F.H.; Björklund, A. Neural grafting in a rat model of Huntington's disease: Progressive neurochemical changes after neostriatal ibotenate lesions and striatal tissue grafting. Neuroscience 1985, 16, 799-817
212. Hantraye, P.; Riche, D.; Maziere, M.; Isacson, O. A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp. Neurol. 1990, 108, 91-104.
213. Pérez-de la Cruz, V.; Königsberg, M.; Santamaría, A. Kynurenine pathway and disease: An overview. CNS Neurol. Disord. Drug Targets 2007a, 6, 398-410.
214. Dang, Y.; Dale, W.E.; Brown, O.R. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway. Free Radic. Biol. Med. 2000, 15, 615-624.
215. Guidetti, P.; Luthi-Carter, R.E.; Augood, S.J.; Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 2004, 17, 455-461.
216. González-Cortés, C.; Santamaría, A. New Perspectives on Brain Cell Damage, Neurodegeneration and Neuroprotective Strategies; Santamaría, A., Jiménez-Capdeville, M.E., Eds. Research Signpost 2007, 37-60.
217. Santamaría, A., Jiménez-Capdeville, M.E.; Camacho, A., Rodríguez-Martínez, E.; Flores, A.; Galván-Arzate, S. In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 2001, 12, 2693-2696.
218. Stone, T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45, 309-379.
219. Heyes, M.P.; Lackner, A.; Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and Lkynurenine in acute septicemia. J. Neurochem. 1990, 55, 338-341.
220. Heyes ,M.P.; Mefford, I.N.; Quearry, B.J.; Dedhia, M.; Lackner, A. Increased ratio of quinolinic acid to kynurenic acid in cerebrospinal fluid of D retrovirus-infected rhesus macaques: Relationship to clinical and viral status. Ann. Neurol. 1990, 27, 666-675.
221. Heyes, MP.; Saito, K.; Crowley, JS.; Davis, LE.; Demitrack, M.A.; Der, M.; Dilling, L.A.; Elia, J.; Kruesi, M.J.; Lackner, A.; Larsen, SA.; Lee, K.; Leonard, HL.; Markey, SP.; Martin, A.; Milstein, S.; Mouradian, MM.; Pranzatelli, MR.; Quearry, BJ.; Salazar, A.; Smith, M.; Strauss, SE.; Sunderland, T.; Swedo, SW.; Tourtellotte, WW. Quinolinic acid and kynurenine pathwaymetabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115, 1249-1273.
222. Moroni, F.; Lombardi, G.; Carlà, V.; Pellegrini, D.; Carassale, G.L.; Cortesini, C. Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy. J. Neurochem. 1986, 46, 869-874.
223. Ogawa, T.; Matson, W.R.; Beal, M.F.; Myers, R.H.; Bird, E.D.; Milbury, P.; Saso, S. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992, 42, 1702-1706.
224. Schwarcz, R.; Okuno, E.; White, R.J.; Bird, E.D.; Whetsell, W.O., Jr. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl. Acad. Sci. USA 1988, 85, 4079-4081.
225. Stone, T.W. Endogenous neurotoxins from tryptophan. Toxicology 2001, 39, 61-73.
226. Stone, T.W.; Connick, J.H. Quinolinic acid and other kynurenines in the central nervous system. Neuroscience 1985, 15, 597-617.
227. During, M.J., Heyes, M.P.; Freese, A.; Markey, S.P.; Martin, J.B.; Roth, R.H. Quinolinic acid concentrations in striatal extracellular fluid reach potentially neurotoxic levels following systemic L-tryptophan loading. Brain Res. 1989, 476, 384-387.
228. Foster, A.C.; Collins, J.F.; Schwarcz, R. On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology 1983, 22, 1331-1342.
229. Santamaría, A.; Ríos, C. MK-801, an N-methyl-D-aspartate receptor antagonist, blocks quinolinic acid-induced lipid peroxidation in rat corpus striatum. Neurosci. Lett. 1993, 159, 51-54.
230. Shear, D.A.; Dong, J.; Gundy, C.D.; Haik-Creguer, K.L.; Dunbar, G.L. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 1998, 22, 1217-1240.
231. Behan, W.M.; McDonald, M.; Darlington, L.G.; Stone ,T.W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: Protection by melatonin and deprenyl. Br. J. Pharmacol. 1999, 128, 1754-1760.
232. Pérez-De La Cruz, V.; González-Cortés, C.; Galván-Arzate, S.; Medina-Campos, O.N.; Pérez- Severiano, F.; Ali, S.F.; Pedraza-Chaverrí, J.; Santamaría, A. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington's disease in rats: Protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience 2005, 135, 463-474.
233. Rodríguez-Martínez, E.; Camacho, A.; Maldonado, P.D.; Pedraza-Chaverrí, J.; Santamaría, D.; Galván-Arzate, S.; Santamaría, A. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 2000, 858, 436-439.
234. Stone, T.W.; Behan, W.M.; MacDonald, M.; Darlington, L.G. Possible mediation of quinolinic acid-induced hippocampal damage by reactive oxygen species. Amino Acids. 2000, 19, 275-281.
235. del Río, P.; Montiel, T.; Chagoya, V.; Massieu, L. Exacerbation of excitotoxic neuronal death induced during mitochondrial inhibition in vivo: Relation to energy imbalance or ATP depletion? Neuroscience 2007, 146, 1561-1570.
236. del Río, P.; Massieu, L. Mild mitochondrial inhibition in vivo enhances glutamate-induced neuronal damage through calpain but not caspase activation: Role of ionotropic glutamate receptors. Exp. Neurol. 2008, 212, 179-188.
237. Henneberry, R.C.; Novelli, A.; Cox, J.A.; Lysko, P.G. Neurotoxicity at the N-methyl-Daspartate receptor in energy-compromised neurons. An hypothesis for cell death in aging and disease. Ann. N.Y. Acad. Sci. 1989a, 568, 225-233.
238. Henneberry, R.C.; Novelli, A.; Vigano, M.A.; Reilly, J.A.; Cox, J.A.; Lysko, P.G. Energy-related neurotoxicity at the NMDA receptor: A possible role in Alzheimer's disease and related disorders. Prog. Clin. Biol. Res. 1989b, 317, 143-156.
239. Greene, J.G.; Greenamyre, J.T.; Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo. J. Neurochem. 1996, 66, 637-643.
240. Ikonomidou, C.; Turski, L. Neurodegenerative disorders: Clues from glutamate and energy metabolism. Crit. Rev. Neurobiol. 1996, 10, 239-263.
241. Massieu, L.; García, O. The role of excitotoxicity and metabolic failure in the pathogenesis of neurological disorders. Neurobiology (Bp). 1998, 6, 99-108.
242. Jacquard, C.; Trioulier, Y.; Cosker, F.; Escartin, C.; Bizat, N.; Hantraye, P.; Cancela, J.M.; Bonvento, G.; Brouillet, E. Brain mitochondrial defects amplify intracellular [Ca2+] rise and neurodegeneration but not Ca2+ entry during NMDA receptor activation. FASEB J. 2006, 20, 1021-1023.
243. Bazzett, T.J.; Falik, R.C.; Becker, J.B.; Albin, R.L. Synergistic effects of chronic exposure to subthreshold concentrations of quinolinic acid and malonate in the rat striatum. Brain Res. 1996, 718, 228-232.
244. Ryu, J.K.; Kim, S.U.; McLarnon, J.G. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp. Neurol. 2004, 187, 150-159.
245. Guidetti, P.; Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 1999, 11, 3857-3863.
246. Fatokun, A.A.; Stone, T.W.; Smith, R.A. Prolonged exposures of cerebellar granule neurons to Snitroso- N-acetylpenicillamine (SNAP) induce neuronal damage independently of peroxynitrite. Brain Res. 2008, 1230, 265-272.
247. Márquez-Valadez, B.; Lugo-Huitrón, R.; Valdivia-Cerda, V.; Miranda-Ramírez, L.R.; Pérez-De La Cruz V.; González- Cuahutencos, O.; Rivero-Cruz, I.; Mata, R.; Santamaría, A.; Pedraza- Chaverrí, J. The natural xanthone alpha-mangostin reduces oxidative damage in rat brain tissue. Nutr. Neurosci. 2009, 12, 35-42.
248. Sudati, J.H.; Fachinetto, R.; Pereira, R.P.; Boligon, A.A.; Athayde, M.L.; Soares, F.A.; de Vargas-Barbosa, N.B.; Rocha, J.B. In vitro antioxidant activity of Valeriana officinalis against different neurotoxic agents. Neurochem. Res. 2009, 34, 1372-1379.
249. Kumar, P.; Kumar, A. Neuroprotective effect of cyclosporine and FK506 against 3- nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: Possible role of nitric oxide. Neurosci. Res. 2009, 63, 302-314.
250. Ubhi, K.; Lee, P.H.; Adame, A.; Inglis, C.; Mante, M.; Rockeinstein, E.; Stefanova, N.; Wenning, G.K.; Masliah, E. Mitochondrial inhibitor 3-nitropropionic acid enhances oxidative modifications of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J. Neurosci. Res. 2009, 87, 2728-2739.
251. Pandey, M.; Borah, A.; Varghese, M.; Barman, P.K.; Mohanakumar K.P.; Usha, R. Strital dopamine level contributes vto hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem. Int. 2009, 55, 431-437.
252. Medina-Navarro, R.; Guerrero-Linares, I. Whole body hyperthermia reduced oxidative stress in the striatum of rats in an animal model of mitochondrial toxicity with 3-nitropropionic acid. Int. J. Hyperthermia 2009, 25, 280-288.
253. Yang, L.; Calingasan, N.Y.; Wille, E.J.; Cormier, K.; Smith, K.; Ferrante, R.J.; Beal, M.F. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 2009, 109, 1427-1439.
254. Kumar, P.; Kalonia, H.; Kumar, A. Sesamol attenuate 3-nitropropionic acid-induced Huntingtonlike behavioral, biochemical, and cellular atlerations in rats. J. Asian Nat. Prod. Res. 2009, 11, 439-450.
255. Kumar, P.; Kumar, A. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: A novel nitric oxide mechanism. Food Chem. Toxicol. 2009, 47, 2522-2530.
256. Kumar, P.; Kumar, A. Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. J. Med. Food 2009, 12, 591-600.
257. Lagoa, R.; López-Sánchez, C.; Samhan-Arias, A.K.; Gañan, C.M.; García-Martínez, V.; Gutíerrez-Merino, C. Kaempferol protects against rat striatal degeneration induced by 3- nitropropionic acid. J. Neurochem. 2009, 111, 473-487.
258. Al Mutairy, A.; Al Kadasah, S.; Elfaki, I.; Arshaduddin, M.; Malik, D.; Al Moutaery, K.; Tariq,M. Trolox ameliorates 3-nitropropionic acid -induced neurotoxicity in rats. Neurotoxicol. Teratol. 2009, In press.
259. Tasset, I.; Pérez-De La Cruz, V.; Elinos-Calderón, D.; Carrillo-Mora, P.; González-Herrera, I.G., Luna-López, A.; Königsberg, M.; Pedraza-Chaverrí, J.; Maldonado, P.D.; Ali, S.F.; Túnez, I.; Santamaría, A. Protective effect of tert-butylhydroquinone on the quinolinic acid-induced toxicity in rat striatal slices: Role of the Nrf2-antioxidant response element pathway. Neurosignals 2010, 18, 24-31.
260. Elinos-Calderón, D.; Robledo-Arratia, Y.; Pérez-De La Cruz, V.; Padraza-Chaverrí, J.; Ali, S.F.; Santamaría, A. Early nerve ending rescue from oxidative damage and energy failure by L-carnitine as post-treatment in two neurotoxic models in rat: Recovery of antioxidant and reductive capacities. Exp. Brain Res. 2009, 197, 287-296.
261. Kada, S.; Nakagawa, T.; Ito, J. A mouse model for degeneration of the spiral ligament. J. Assoc. Res. Otolaryngol. 2009, 10, 161-172.
262. Uo, T.; Veenstra, T.D.; Morrison, R.S. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two disctinct mechanisms. J. Neurosci. 2009, 29, 2824-2832.
263. Liot, G.; Bossy, B.; Lubitz, S.; Kushnareva, Y.; Sejbuk, N.; Bossy-Wetzel, E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDAand ROS-dependent pathway. Cell Death Differ. 2009, 16, 899-909.
264. Zhang, X.D.; Wang, Y.; Wang, Y.; Zhang, X.; Han, R.; Wu, J.C.; Liang, Z.Q.; Gu, Z.L.; Han, F.; Fukunaga, K.; Qin, Z.H. p53 mediates mitochondria dysfunction-triggered autophagy activation and cell death in rat striatum. Autophagy 2009, in press.
265. Singh, S.; Misiak, M.; Beyer, C.; Arnold, S. Cytochrome c oxidase isoform IV-2 is involved in 3-nitropropionic acid-induced toxicity in striatal astrocytes. Glia 2009, 57, 1480-1491.
266. Kraft, J.C.; Osterhaus, G.L.; Ortiz, A.N.; Garriz, P.A.; Johnson, M.A. In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid. Neuroscience 2009, 161, 940-949.
267. Diwakarla, S.; Mercer. L.D.; Kardashsyan, L.; Chu, P.W.; Shin, Y.S.; Lau, C.L., Hughes, M.L.; Nagley, P., Beart, P.M. GABAergic striatal neurons exhibit caspase-independent, mitochondrially mediated programmed cell death. J. Neurochem. 2009, 109, 198-206.
268. Wu, C.L.; Hwang, C.S.; Yang, D.I. Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons. Neurotoxicology 2009, 30, 718-726.
269. Wu, C.L.; Chen, S.D.; Hwang, C.S.; Yang, D.I. Sonic hedgehog mediates BDNF-induced neuroprotection against mitochondrial inhibitor 3-nitropropionic acid. Biochim. Biophys. Res. Commun. 2009, 385, 112-117.
270. Almeida, S.; Laço, M.; Cunha-Oliveira, T.; Oliveira, C.R.; Rego, A.C. BDNF regulates BIM expression levels in 3-nitropropionic acid-treated cortical neurons. Nuerobiol. Dis. 2009, 35, 448-456.
271. Wei, Z.; Chigurupati, S.; Bagsiyao, P.; Henriquez, A.; Chan, S.L. The brain uncoupling protein UCP4 attenuates mitochondrial toxin-induced cell death: Role of extracellular signal-regulated kinases in bioenergetics adaptation and cell survival. Neurotox. Res. 2009, 16, 14-29.